KKPC.F Stock Overview
Produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Kaken Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥24.01 |
| 52 Week High | JP¥28.00 |
| 52 Week Low | JP¥22.30 |
| Beta | 0.25 |
| 11 Month Change | -12.69% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 171.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| KKPC.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 2.2% |
| 1Y | n/a | 11.8% | 32.6% |
Return vs Industry: Insufficient data to determine how KKPC.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KKPC.F performed against the US Market.
Price Volatility
| KKPC.F volatility | |
|---|---|
| KKPC.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KKPC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KKPC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 1,135 | Hiroyuki Horiuchi | www.kaken.co.jp |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens.
Kaken Pharmaceutical Co., Ltd. Fundamentals Summary
| KKPC.F fundamental statistics | |
|---|---|
| Market cap | US$1.08b |
| Earnings (TTM) | US$118.35m |
| Revenue (TTM) | US$565.99m |
9.1x
P/E Ratio1.9x
P/S RatioIs KKPC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KKPC.F income statement (TTM) | |
|---|---|
| Revenue | JP¥87.25b |
| Cost of Revenue | JP¥34.32b |
| Gross Profit | JP¥52.92b |
| Other Expenses | JP¥34.68b |
| Earnings | JP¥18.24b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 481.68 |
| Gross Margin | 60.66% |
| Net Profit Margin | 20.91% |
| Debt/Equity Ratio | 2.5% |
How did KKPC.F perform over the long term?
See historical performance and comparison